Pathological complete response from oral chemotherapy combined with trans-arterial chemotherapy and embolization in an unresectable gastric cancer patient: A case report

Zhaoran Su, Kuanshan Shu, Min Kang, Guihe Wang, Zhaoran Su, Kuanshan Shu, Min Kang, Guihe Wang

Abstract

Rationale: Gastric cancer is still one of the most common cancer in East Asia. More than 70% gastric cancer patients are diagnosed at an advanced stage in China. Moreover, about 10% cases are unresectable which usually suffer a poor prognosis with a median survival time of 5 to 12 months. In recent years, some clinical studies found that many unresectable gastric cancer cases could get opportunity for surgery after treatment that improve prognosis significantly PATIENT CONCERNS:: 64-year-old male patient was admitted with upper abdominal pain. Upper gastrointestinal endoscopy showed a large ulcerated tumor located from the cardia to the anterior wall of the upper gastric body. Histopathological examination showed it was moderately differentiated adenocarcinoma. Computed tomography (CT) scan image showed a large bulging mass with internal ulcer at the lesser curvature wall, left gastric artery and coeliac trunk were surrounded by fused lymph nodes.

Diagnoses: Based on the histopathological examination and imaging findings, patient was diagnosed advanced gastric cancer and hardly to resect radically.

Intervention: Oral chemotherapy combined with trans-arterial chemotherapy and embolization (TACE) was initiated. Eight weeks after initial therapy, radical laparoscopy-assisted total gastrectomy with D2 lymph node dissection and Roux-en-Y anastomosis were performed successfully.

Outcomes: Patient was discharged on postoperative day 11 without complications. Histological analysis of the specimen and resected 31 lymph nodes revealed no malignancy. The patient experienced a pathological complete response (pCR).

Lessons: In this case, oral chemotherapy combined with TACE which was rarely reported in the treatment of unresectable gastric cancer achieves a great therapeutic benefit. Although further clinical studies will be needed to establish, it may be a potent strategy for degrading stage and supplying a new chance for surgery.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Upper gastrointestinal endoscopy showed a large ulcerated tumor located from the cardia to the anterior wall of the upper gastric body.
Figure 2
Figure 2
CT showed a large bulging mass with internal ulcer at the lesser curvature wall of the gastric upper body near the cardia (A), left gastric artery and coeliac trunk were surrounded by fused lymph nodes (C). After conversion treatment, the primary tumor (B) and enlarged lymph nodes were significantly reduced (D). CT = computed tomography.
Figure 3
Figure 3
GSPs was injected into the tumor blood vessels under the guidance of DSA. DSA = digital subtraction angiography, GSPs = gelatin sponge particles.
Figure 4
Figure 4
The laparoscopic view showed the gastric serosal surface of lesion was smooth.
Figure 5
Figure 5
Specimen examination showed a 4 cm × 5 cm cicatricial lesion located at the lesser curvature wall of the gastric upper body near the cardia.
Figure 6
Figure 6
Histological analysis of the specimen from the scar revealed no malignancy.

References

    1. Qiu M, Zhou Y, Zhang X, et al. Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients. BMC Cancer 2014;14:823.
    1. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007;25:3205–9.
    1. Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta analysis based on aggregate data. J Clin Oncol 2006;24:2903–9.
    1. Inoue K, Nakane Y, Kogire M, et al. Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer. Eur J Surg Oncol 2012;38:143–9.
    1. Kim SW. The result of conversion surgery in gastric cancer patients with peritoneal seeding. J Gastric Cancer 2014;14:266–70.
    1. Wu X, Li Z, Li Z, et al. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis. J Surg Oncol 2015;111:840–7.
    1. Ratosa I, Oblak I, Anderluh F, et al. Preoperative treatment with radiochemotherapy for locally advanced gastroesophageal junction cancer and unresectable locally advanced gastric cancer. Radiol Oncol 2015;49:163–72.
    1. Cascinu S, Scartozzi M, Labianca R, et al. High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 2004;90:1521–5.
    1. Sym SJ, Chang HM, Ryu MH, et al. Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer. Ann Surg Oncol 2010;17:1024–32.

Source: PubMed

3
Suscribir